Literature DB >> 29479067

Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.

Paolo Strati1, Alessandra Ferrajoli1, William G Wierda1, Nitin Jain1, Philip A Thompson1, Susan M O'Brien1, Katy Rezvani1, Hagop M Kantarjian1, Jan A Burger1, Christina O Hinojosa1, Michael J Keating1, Zeev Estrov2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29479067     DOI： 10.1038/s41375-018-0059-3

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Authors:  Paolo Strati; Koichi Takahashi; Christine B Peterson; Michael J Keating; Philip A Thompson; Naval G Daver; Nitin Jain; Jan A Burger; Zeev Estrov; Susan M O'Brien; Hagop M Kantarjian; William G Wierda; P Andrew Futreal; Alessandra Ferrajoli
Journal:  Blood Adv       Date:  2019-05-14

Review 2.  Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach.

Authors:  Paolo Strati; Alessandra Ferrajoli
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.